BVX has identified a unique, cancer-restricted antigen fingerprint, absent from healthy cells, which can be exploited to produce cancer selective therapeutics. The Bi-Cygni® technology has been developed to exploit this concept and expedite the development of bispecific therapeutics with an improved therapeutic index. Based on BVX's work to date, these ADCs demonstrate superior potency and tumour selectivity compared to conventional ADCs. The main country of operation is in the UK.
CEO: |
Tiffany Jane Thorn |
Non-Executive Chairman: |
Michael Kauffman |
Senior Independent Non-Executive Director: |
William Drummond Paris |
Independent Non-Executive Director: |
Robert Edward Hawkins, Susan Day Lowther |
Address: |
Mereside, Alderley Park ,Alderley Edge, Macclesfield, United Kingdom |
Phone: |
|
Fax: |
|
Website: |
http://www.bivictrix.com/ |
Email: |
|